Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Flow cytometric gating strategy for human CD8+ T cell analysis.
  • Fig. S2. Correlation of glycolytic and respiratory changes in CD8+ T cells of patients with AML relapse after allo-HCT.
  • Fig. S3. Transcriptomic analysis of CD8+ T cells incubated with AML supernatant.
  • Fig. S4. Flow cytometric gating strategy for cell cycle analysis.
  • Fig. S5. Mass spectrometric analysis of metabolites of cell culture supernatants.
  • Fig. S6. Altered signaling profile in LA-challenged T cells.
  • Fig. S7. Influence of soluble factors on T cell metabolism.
  • Fig. S8. Influence of IL-3 addition on T cell metabolism.
  • Fig. S9. NaBi treatment of LA-challenged T cells normalizes metabolite pools.
  • Fig. S10. Inhibition of MCT1 leads to reduced proliferative activity.
  • Fig. S11. Higher concentrations of MCT1 inhibitor do not further decrease glycolytic and proliferative activity.
  • Fig. S12. LA impairs CD4+ T cell metabolism, proliferation, and cell cycle, which can be rescued by NaBi administration.
  • Fig. S13. LDHA inhibition in AML cells reduces lactate secretion and improves metabolic activity of T cells challenged with AML medium.
  • Fig. S14. Intracellular pH under extracellular acid pH, sodium, or buffer treatment.
  • Fig. S15. Expression of bicarbonate transporters on CD8+ T cells.
  • Fig. S16. Short incubation with LA leads to initial increase in carbon metabolism independent of NaBi administration.
  • Fig. S17. NaBi treatment does not increase GVHD severity.
  • Fig. S18. Metabolic and immune phenotypic analysis of patients with relapsed AML under bicaNorm treatment.
  • Fig. S19. Proposed mechanism for metabolic boost of NaBi treatment on T cells challenged with leukemia-derived LA.
  • Table S1. Clinical, molecular, and cytogenetic characteristics of patients with AML at primary diagnosis.
  • Table S2. Clinical, molecular, and cytogenetic characteristics of patients with AML at relapse.
  • Table S3. Chemotherapy conditioning regimens and transplant characteristics of patients with relapse.
  • Table S4. Clinical, molecular, and cytogenetic characteristics of patients with AML in remission.
  • Table S5. Chemotherapy conditioning regimens and transplant characteristics of patients in remission.
  • Table S6. Clinical, molecular, and cytogenetic characteristics of patients with AML treated with NaBi.
  • Table S7. Antibodies for flow cytometry.
  • Table S8. Additional cell staining dyes.
  • Table S9. Antibodies for Western blots.
  • References (2843)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Karyotype and molecular abnormalities of each patient.
  • Data file S2 (Microsoft Excel format). Source data for main figures.
  • Data file S3 (Microsoft Excel format). Source data for supplementary figures.
  • Data file S4 (.m format). MATLAB for NMR analysis.
  • Data file S5 (.txt format). MATLAB for NMR analysis options.